Capricor Therapeutics (CAPR) Earnings Dates, Call Summary & Reports

Compare

1,275 Followers

Earnings Data

Report Date

May 20, 2026

After Close (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

-0.52

Last Year’s EPS

-0.53

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 8 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Mar 12, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed predominantly positive operational and clinical developments: regulatory momentum with BLA acceptance and a clear PDUFA date, robust Phase 3 HOPE-3 efficacy and safety data (including a 91% slowing of LV ejection fraction decline and supportive functional and imaging endpoints), manufacturing readiness and planned capacity expansion, and recent financings and NASDAQ uplisting to support near-term execution. Counterbalancing these positives are biotech-typical near-term challenges—zero product revenue, materially higher operating expenses and widened net losses in 2025, remaining labeling and regulatory uncertainties, limited neutralization signals in the early StealthX readout, and a manufacturing ramp timeline that may constrain supply until expansions come online. Overall, the strategic and clinical wins (BLA acceptance, pivotal data, manufacturing inspection success, strengthened capital base) outweigh the financial and programmatic risks discussed on the call.

Company Guidance

Management said the resubmitted BLA was accepted and assigned a PDUFA target action date of August 22, 2026, supported by the pivotal HOPE‑3 trial (106 patients) which met its primary PUL endpoint and all Type‑1‑error‑controlled secondary endpoints, with left ventricular ejection fraction showing a 91% slowing of disease progression (statistically significant overall and p=0.01 in the cardiomyopathy subgroup); the program has >800 IV infusions across studies, >100 OLE patients (some on continuous infusions up to five years), and manufacturing passed the FDA pre‑license inspection with all Form‑483s addressed and current capacity to support ~250 patients/year (with stockpiling plans) and an expansion (≈6 additional clean rooms) expected to support ~2,500 patients/year or ~10,000 doses annually coming online in late‑2027; financially the company reported cash of approximately $318,000,000 as of 12/31/2025 (the CFO also reported cash, cash & marketable securities of ~$3.181 billion), received $162,000,000 net proceeds from a December offering and drew $75,000,000 under an ATM, had 2025 revenue of $0 (vs ~$22.3M FY‑2024), FY‑2025 operating expenses of ~$108.1M (vs $64.8M FY‑2024) and a FY‑2025 net loss of ~$105.0M (vs $40.5M FY‑2024), believes current capital funds operations into 2027, and noted eligibility for a transferable priority review voucher (sunset 09/30/2029) upon approval.

BLA Acceptance and PDUFA Date

FDA accepted the company's Class II BLA resubmission for deramycin and assigned a PDUFA target action date of 2026-08-22, marking a major regulatory milestone toward potential approval.

Strong HOPE-3 Phase 3 Efficacy Data

HOPE-3 (n=106) met its primary endpoint (Performance of the Upper Limb) and all Type 1 error‑controlled secondary endpoints; left ventricular ejection fraction showed a 91% slowing of disease progression in all evaluable patients and reached stronger significance in the cardiomyopathy subgroup (p=0.01).

Functional and Imaging Benefits Demonstrated

Statistically significant improvement on a home-based Duchenne Video Assessment (DVA EAT10 BITE) corroborated PUL results (≈50 patients per arm completed DVA); MRI late gadolinium enhancement data showed meaningful reduction in cardiac fibrosis in treated patients versus placebo.

Safety and Long-Term Exposure

Deramycin safety profile reinforced by >800 intravenous infusions across studies, evidence of long-term safety in open-label extension studies with some patients receiving continuous infusions up to five years and >100 patients in OLE collectively.

Manufacturing and Commercial Readiness

In-house GMP facility in San Diego completed FDA pre-license inspection; all Form 483 observations addressed. Current capacity supports ~250 patients/year with expansion (adding ~6 clean rooms) planned to support ~2,500 patients/year (~10,000 doses annually) with full capacity expected online in late 2027.

Strengthened Balance Sheet and Capital Raise

Management stated cash position strengthened by late-December financings. CFO disclosed incremental financing events in Dec 2025: public offering net proceeds $162M and ATM draw of $75M; company believes cash is sufficient to fund operations into 2027 (management cited ~$318M cash; CFO provided detailed financing amounts).

Strategic and Visibility Wins

Company was approved for uplisting to the NASDAQ Global Select Market; management highlighted potential eligibility for a transferable Priority Review Voucher upon approval and submission of full HOPE-3 dataset for peer-reviewed publication.

Exosome Platform Progress

Phase 1 StealthX COVID vaccine (Project NextGen, NIAID) shown to be well tolerated; preclinical data and platform learnings support further engineering of exosomes for muscle targeting and multiple payloads with IND-enabling programs targeting IND filing in 2027.

Capricor Therapeutics (CAPR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CAPR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 20, 2026	2026 (Q1)	-0.52 / -	-0.53	―	―	―
Mar 12, 2026	2025 (Q4)	-0.51 / -0.62	-0.16	-287.50% (-0.46)	―
Nov 10, 2025	2025 (Q3)	-0.55 / -0.54	-0.38	-42.11% (-0.16)	―
Aug 11, 2025	2025 (Q2)	-0.48 / -0.57	-0.35	-62.86% (-0.22)	―
May 13, 2025	2025 (Q1)	-0.32 / -0.53	-0.31	-70.97% (-0.22)	―
Mar 19, 2025	2024 (Q4)	-0.17 / -0.16	-0.02	-700.00% (-0.14)	―
Nov 13, 2024	2024 (Q3)	-0.36 / -0.38	-0.25	-52.00% (-0.13)	―
Aug 07, 2024	2024 (Q2)	-0.36 / -0.35	-0.29	-20.69% (-0.06)	―
May 13, 2024	2024 (Q1)	-0.11 / -0.31	-0.31	0.00% (0.00)	―
Feb 29, 2024	2023 (Q4)	-0.09 / -0.02	-0.31	93.55% (+0.29)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CAPR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 12, 2026	$33.42	$30.50	-8.74%
Nov 10, 2025	$5.56	$6.20	+11.51%
Aug 11, 2025	$7.82	$8.04	+2.88%
May 13, 2025	$7.30	$7.67	+5.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Capricor Therapeutics (CAPR) report earnings?

Capricor Therapeutics (CAPR) is schdueled to report earning on May 20, 2026, After Close (Confirmed).

What is Capricor Therapeutics (CAPR) earnings time?

Capricor Therapeutics (CAPR) earnings time is at May 20, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CAPR EPS forecast?

CAPR EPS forecast for the fiscal quarter 2026 (Q1) is -0.52.